 |
|
Continuation of Statin Treatment and All-Cause MortalityA Population-Based Cohort Study
Varda Shalev, MD;
Gabriel Chodick, PhD;
Haim Silber, MD;
Ehud Kokia, MD;
Joseph Jan, MHA;
Anthony D. Heymann, MD
Arch Intern Med. 2009;169(3):260-268.
Background The beneficial effects of statins on cardiovascular mortality in secondary prevention have been established in several long-term, placebo-controlled trials. However, the value of statin therapy in reduction of overall mortality in patients without coronary heart disease (CHD) is questionable. This study evaluated the effect of statin therapy in subjects with no indication of cardiovascular disease (primary prevention) and patients with known CHD (secondary prevention).
Methods This retrospective cohort study included 229 918 adult enrollees in a health maintenance organization in Israel who initiated statin treatment from 1998 through 2006 (mean age, 57.6 years; 50.8% female). Proportion of days covered (PDC) with statins was measured by the number of dispensed statin prescriptions during the interval between the date of the first statin prescription and the end of follow-up.
Results During a mean of 4.0 and 5.0 years of follow-up, there were 4259 and 8906 deaths among the primary prevention and secondary prevention cohorts, respectively. In both cohorts, continuity of treatment with statins (PDC,  90%) conferred at least a 45% reduction in risk of death compared with patients with a PDC of less than 10%. A stronger risk reduction was calculated among patients with high baseline low-density lipoprotein cholesterol level and patients initially treated with high-efficacy statins.
Conclusions Better continuity of statin treatment provided an ongoing reduction in mortality among patients with and without a known history of CHD. The observed benefits from statins were greater than expected from randomized clinical trials.
Author Affiliations: Medical Division, Maccabi Healthcare Services (Drs Shalev, Chodick, Silber, Kokia, and Heymann and Mr Jan), and Sackler Faculty of Medicine, Tel Aviv University (Drs Shalev, Chodick, and Heymann), Tel Aviv, Israel.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTERS
Association Not Causation
Beatrice A. Golomb and Sabrina Koperski
Arch Intern Med. 2009;169(11):1079.
EXTRACT
| FULL TEXT
Continuation of Statin Treatment and Mortality: A Note of Caution on Excessive Benefits
Kristian B. Filion, Verena Schneider-Lindner, Igor Karp, Linda E. Lévesque, James M. Brophy, and Samy Suissa
Arch Intern Med. 2009;169(11):1080.
EXTRACT
| FULL TEXT
Continuation of Statin Treatment and Mortality: A Note of Caution on Excessive Benefits—Reply
Varda Shalev and Gabriel Chodick
Arch Intern Med. 2009;169(11):1080-1081.
EXTRACT
| FULL TEXT
The Healthy Adherer Effect
Frank Andersohn and Stefan N. Willich
Arch Intern Med. 2009;169(17):1635-1636.
EXTRACT
| FULL TEXT
The Healthy Adherer Effect—Reply
Varda Shalev and Gabriel Chodick
Arch Intern Med. 2009;169(17):1636.
EXTRACT
| FULL TEXT
RELATED ARTICLE
In This Issue of Archives of Internal Medicine
Arch Intern Med. 2009;169(3):216.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Value-Driven Spine Care
Nash
American Journal of Medical Quality 2009;24:3S-3S.
The Healthy Adherer Effect
Andersohn and Willich
Arch Intern Med 2009;169:1635-1636.
FULL TEXT
Continuation of Statin Treatment and Mortality: A Note of Caution on Excessive Benefits
Filion et al.
Arch Intern Med 2009;169:1080-1080.
FULL TEXT
Association Not Causation
Golomb and Koperski
Arch Intern Med 2009;169:1079-1079.
FULL TEXT
Continuation of Statin Treatment and Mortality: A Note of Caution on Excessive Benefits--Reply
Shalev and Chodick
Arch Intern Med 2009;169:1080-1081.
FULL TEXT
|
